n-methyl-3,4-methylenedioxyamphetamine has been researched along with Diabetes Insipidus, Neurogenic in 1 studies
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.
Diabetes Insipidus, Neurogenic: A genetic or acquired polyuric disorder caused by a deficiency of VASOPRESSINS secreted by the NEUROHYPOPHYSIS. Clinical signs include the excretion of large volumes of dilute URINE; HYPERNATREMIA; THIRST; and polydipsia. Etiologies include HEAD TRAUMA; surgeries and diseases involving the HYPOTHALAMUS and the PITUITARY GLAND. This disorder may also be caused by mutations of genes such as ARVP encoding vasopressin and its corresponding neurophysin (NEUROPHYSINS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Disruptions of the hypothalamic-pituitary axis can cause an arginine vasopressin deficiency, also known as central diabetes insipidus." | 9.69 | Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial. ( Atila, C; Christ-Crain, M; Eckert, A; Heinrichs, M; Holze, F; Hutter, N; Liechti, ME; Murugesu, R; Rommers, N; Sailer, CO; Varghese, N, 2023) |
| "Disruptions of the hypothalamic-pituitary axis can cause an arginine vasopressin deficiency, also known as central diabetes insipidus." | 5.69 | Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial. ( Atila, C; Christ-Crain, M; Eckert, A; Heinrichs, M; Holze, F; Hutter, N; Liechti, ME; Murugesu, R; Rommers, N; Sailer, CO; Varghese, N, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atila, C | 1 |
| Holze, F | 1 |
| Murugesu, R | 1 |
| Rommers, N | 1 |
| Hutter, N | 1 |
| Varghese, N | 1 |
| Sailer, CO | 1 |
| Eckert, A | 1 |
| Heinrichs, M | 1 |
| Liechti, ME | 1 |
| Christ-Crain, M | 1 |
1 trial available for n-methyl-3,4-methylenedioxyamphetamine and Diabetes Insipidus, Neurogenic
| Article | Year |
|---|---|
Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial.
Topics: Arginine; Case-Control Studies; Cross-Over Studies; Diabetes Insipidus, Neurogenic; Diabetes Mellitu | 2023 |